Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both

作者
Yudi Chen,Miao Yu,Xiaojie Huang,Ping Tu,Peikun Shi,Marcus Maurer,Zuotao Zhao
出处
期刊:World Allergy Organization Journal [Elsevier BV]
卷期号:14 (1): 100501-100501 被引量:58
标识
DOI:10.1016/j.waojou.2020.100501
摘要

Background Chronic urticaria (CU) is a common skin disorder, which can be further divided into chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Omalizumab is effective and safe for difficult-to-treat CSU based on clinical trials. However, there are limited data comparing the therapeutic effect of omalizumab for patients with CSU, CIndU, and CSU plus CIndU. Meanwhile, there is still no reliable predictor for treatment response or relapse. Our study was conducted to collect real-world clinical data on omalizumab treatment in patients with CSU, CIndU, and both. Methods This was an observational, retrospective chart review of patients with CU initiating omalizumab treatment between February 2018 and May 2020 (maximum 28 months follow-up). Results A total of 138 patients were included, 87 with CSU alone, 33 with different forms of CIndU, and 18 with both. A total of 87.0% (n = 120/138) of the CU patients responded to omalizumab therapy, among which 65.2% (n = 90/138) of the patients showed complete response and 21.7% (n = 30/138) of the patients showed partial response. The therapeutic effect and speed of onset of effect for omalizumab were comparable among patients with CSU, CIndU, or both. Autologous serum skin test (ASST)-positive patients were more likely to show a slow response to omalizumab therapy ( P = 0.043). Non-responders had lower baseline total IgE levels (35.0 vs 121.5 kU/L, P < 0.001). The proportion of patients with low total IgE levels in non-responders was significantly higher than that of responders (61.1% vs. 14.5%, P < 0.001). Also, more non-responder patients had elevated thyroid autoantibodies than responders (50.0% vs. 23.0%, P = 0.041). The median ratio of serum IgG-anti-TPO to serum total IgE in non-responders was significantly higher compared with responders (1.22 vs. 0.09, P < 0.001). Non-responders also had shorter treatment periods (4.5 vs 6.0 months, P = 0.035) compared with responders. Two of 3 patients (67.4%, n = 29/43) experienced relapse after ceasing omalizumab therapy. These patients had longer disease durations (52.0 vs. 15.0 months, P = 0.007) and higher baseline total IgE levels (179.9 vs. 72.5 kU/L, P = 0.020) than patients who did not relapse. We reinitiated omalizumab treatment for 10 relapsed patients, all of them reported a rapid response after the first injection within the first 4 weeks of retreatment. Conclusion Omalizumab is highly effective in patients with difficult-to-treat CSU, CIndU, or both. Responders tend to have unique immunological features and longer treatment periods. Patients with higher baseline total IgE levels and longer disease durations are more likely to experience rapid relapse after discontinuation of omalizumab.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ZIYE的应助被RR采纳,获得10
刚刚
无敌雪豹大王完成签到,获得积分20
1秒前
小范在学完成签到,获得积分10
1秒前
1秒前
1秒前
维生素发布了新的文献求助10
1秒前
1秒前
2秒前
小鱼给小鱼的求助进行了留言
2秒前
科研小小怪完成签到 ,获得积分10
2秒前
rigelfalcon完成签到,获得积分10
3秒前
3秒前
曲线完成签到,获得积分10
3秒前
只如初发布了新的文献求助10
3秒前
不爱吃花生完成签到 ,获得积分10
3秒前
chloe发布了新的文献求助10
3秒前
小金完成签到,获得积分10
4秒前
4秒前
4秒前
平淡香岚完成签到,获得积分10
4秒前
Ryan123完成签到,获得积分10
4秒前
5秒前
5秒前
大瓶子完成签到,获得积分10
5秒前
爱吃蓝莓完成签到,获得积分10
5秒前
6秒前
璇儿的完成签到,获得积分10
6秒前
6秒前
爆米花的应助被衿_采纳,获得10
6秒前
Geopoison完成签到,获得积分10
6秒前
Miraitowa完成签到 ,获得积分10
6秒前
魔修222完成签到,获得积分10
7秒前
凯子哥完成签到,获得积分10
7秒前
7秒前
7秒前
张大侠完成签到,获得积分20
7秒前
superpharm完成签到,获得积分10
7秒前
无极微光的应助被nosay采纳,获得20
8秒前
Ryan123发布了新的文献求助30
8秒前
小时完成签到 ,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8174136
求助须知:如何正确求助?哪些是违规求助? 9566193
关于积分的说明 21785238
捐赠科研通 7768317
什么是DOI,文献DOI怎么找? 3431698
关于科研通互助平台的介绍 2555912
邀请新用户注册赠送积分活动 2476956